Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial - PubMed (original) (raw)

Randomized Controlled Trial

. 2017 Mar 1;102(3):914-922.

doi: 10.1210/jc.2016-3237.

Affiliations

Randomized Controlled Trial

Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial

Catherine M Viscoli et al. J Clin Endocrinol Metab. 2017.

Abstract

Context: Pioglitazone reduces cardiovascular risk in nondiabetic patients after an ischemic stroke or transient ischemic attack (TIA) but is associated with increased risk for bone fracture.

Objective: To characterize fractures associated with pioglitazone by location, mechanism, severity, timing, and sex.

Design, setting, and patients: Patients were 3876 nondiabetic participants in the Insulin Resistance Intervention after Stroke trial randomized to pioglitazone or placebo and followed for a median of 4.8 years. Fractures were identified through quarterly interviews.

Results: At 5 years, the increment in fracture risk between pioglitazone and placebo groups was 4.9% [13.6% vs 8.8%; hazard ratio (HR), 1.53; 95% confidence interval (CI), 1.24 to 1.89). In each group, ∼80% of fractures were low energy (i.e., resulted from fall) and 45% were serious (i.e., required surgery or hospitalization). For serious fractures most likely to be related to pioglitazone (low energy, nonpathological), the risk increment was 1.6% (4.7% vs 3.1%; HR, 1.47; 95% CI, 1.03 to 2.09). Increased risk for any fracture was observed in men (9.4% vs 5.2%; HR, 1.83; 95% CI, 1.36 to 2.48) and women (14.9% vs 11.6%; HR, 1.32; 95% CI, 0.98 to 1.78; interaction P = 0.13).

Conclusions: Fractures affected 8.8% of placebo-treated patients within 5 years after an ischemic stroke or TIA. Pioglitazone increased the absolute fracture risk by 1.6% to 4.9% and the relative risk by 47% to 60%, depending on fracture classification. Our analysis suggests that treatments to improve bone health and prevent falls may help optimize the risk/benefit ratio for pioglitazone.

Trial registration: ClinicalTrials.gov NCT00091949.

PubMed Disclaimer

Figures

Figure 1.

Figure 1.

Time to first fracture. Overall fractures (A) and those by sex (B, men; C, women) are shown.

Figure 2.

Figure 2.

Risk of fracture by location, overall, and by sex.

Similar articles

Cited by

References

    1. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O’Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR; IRIS Trial Investigators . Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374(14):1321–1331. - PMC - PubMed
    1. Kahn S, Zinman B, Lachin J, Haffner S, Herman W, Holman R, Kravitz B, Yu D, Heise M, Aftring R, Viberti G; A Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care. 2008;31(5):845–851. - PubMed
    1. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn AR; PROactive investigators . Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009;32(3):187–202. - PubMed
    1. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV; RECORD Study Team . Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373(9681):2125–2135. - PubMed
    1. Billington E, Grey A, Bolland M. The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia. 2015;58(10):2238–2246. doi:10.1007/s00125-015-3660-2. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources